
Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
What is the importance and prevalence of treat-to-target?
Marcus H. Snow, MD, from University of Nebraska Medical Center, speaks about the importance of treat-to-target and its goal of disease remission in patients with rheumatoid arthritis. Dr. Snow believes that most physicians already practice an informal treat-to-target therapy.






